trending Market Intelligence /marketintelligence/en/news-insights/trending/MFgrdr0sSo9qzIUaA-cnaQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AstraZeneca terminates collaboration agreement with Regulus Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AstraZeneca terminates collaboration agreement with Regulus Therapeutics

AstraZeneca PLC decided to terminate a 2012 collaboration agreement with Regulus Therapeutics Inc. to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases and oncology.

The termination becomes effective June 9, 2018.

Pursuant to the agreement, Regulus granted AstraZeneca an exclusive, worldwide license to develop, manufacture and commercialize lead compounds designated by AstraZeneca in the course of the collaboration activities against the alliance targets for all human therapeutic uses.

The companies identified RG-125 or AZD4076 as one such clinical candidate in April 2015. Effective upon the termination of the agreement, AstraZeneca's rights with respect to the drug will revert to Regulus.

Regulus also said it will discontinue clinical development of RG-101, a microRNA treatment for hepatitis C, upon completion of the one remaining clinical study, which is expected to occur in July.

Investigation and thorough evaluation of the clinical data from RG-101 has led to the identification of a bilirubin transport mechanism as the likely cause for the cases of hyperbilirubinemia, a condition in which there is too much bilirubin in the blood, in the RG-101 program.

The company believes that a combination of factors including inhibition of conjugated bilirubin transport by RG-101, impaired baseline bilirubin transport in patients and the preferential uptake of RG-101 by hepatocytes contributed to this mechanism.

Applying the learnings from the RG-101 program, alternative compounds targeting miR-122 have been identified that maintain potent hepatitis C antiviral activity while lacking inhibition of the bilirubin transporter. These compounds have the potential for rapid clinical proof-of-concept of a novel, markedly shortened treatment regimen and will be considered for further development pending an updated global commercial market assessment.

RGLS5040, an unconjugated inhibitor of microRNA27, has been discontinued based on a positioning of the compound with respect to the competitive landscape coupled with the results from repeat pharmacology studies. The company continues to work on developing effective therapeutics for genetic forms of cholestatic disease as part of its overall research activities targeting unmet diseases of the liver and kidney.